Trial Profile
Tyrosine kinase inhibors in patients with newly diagnosed chronic myeloid leukemia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jan 2017
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 18 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.